文献速递妇科

非唑奈坦与艾林奈坦治疗绝经女性血管舒缩症状:系统综述与Meta分析

Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2025-01-02

该系统综述与Meta分析纳入7项随机对照试验共4087例绝经女性,评估非唑奈坦与艾林奈坦对比安慰剂治疗血管舒缩症状的疗效与安全性。两种药物均与血管舒缩症状频率和严重程度降低相关,艾林奈坦120mg在频率和严重程度降低方面效应量更大,并显著改善睡眠质量。

要点

  • 非唑奈坦30mg、45mg与艾林奈坦120mg均与血管舒缩症状频率降低相关。
  • 艾林奈坦120mg在症状频率和严重程度降低方面效应量大于非唑奈坦。
  • 艾林奈坦120mg与药物相关不良事件和头痛发生风险降低相关。

核心结论

  • 本Meta分析结果一致提示,非唑奈坦和艾林奈坦与绝经女性血管舒缩症状的获益结局相关。
  • 与安慰剂相比,艾林奈坦在血管舒缩症状频率和严重程度降低方面效应量更大,并大幅改善睡眠质量。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE和Cochrane数据库至2024年8月22日。
  • 纳入7项比较非唑奈坦或艾林奈坦与安慰剂治疗绝经女性血管舒缩症状的随机对照试验,共4087例患者。
  • 采用Mantel-Haenszel法和95%CI分析数据,用I²统计量评估异质性,使用R 4.3.2进行统计分析。

主要发现

  • 非唑奈坦30mg与血管舒缩症状频率降低相关(均数差2.16,95%CI 1.54-2.79,I²=0%)。
  • 非唑奈坦45mg与血管舒缩症状频率降低相关(均数差2.54,95%CI 1.86-3.21,I²=0%)。
  • 艾林奈坦120mg与血管舒缩症状频率降低相关(均数差2.99,95%CI 1.74-4.23,I²=0%)。
  • 非唑奈坦30mg与血管舒缩症状严重程度降低相关(均数差0.20,95%CI 0.09-0.33,I²=0%);非唑奈坦45mg(均数差0.24,95%CI 0.13-0.34,I²=0%);艾林奈坦120mg(均数差0.36,95%CI 0.26-0.46,I²=0%)。
  • 艾林奈坦120mg与睡眠质量显著改善相关(均数差4.65,95%CI 3.73-5.56,I²=0%)。

关键数值与推荐

  • 艾林奈坦120mg组药物相关不良事件发生率11.70% vs 对照组20.75%(RR 0.57,95%CI 0.39-0.82,I²=19%)。
  • 艾林奈坦120mg组头痛发生率2.54% vs 对照组8.0%(RR 0.32,95%CI 0.16-0.64,I²=0%)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in menopausal women. DATA SOURCES: MEDLINE, EMBASE, and Cochrane databases were systematically searched until August 22, 2024. Because the Cochrane Library included all the identified randomized controlled trials (RCTs), it was unnecessary to search ClinicalTrials.gov . The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor symptoms, and menopause. METHODS OF STUDY SELECTION: Only RCTs comparing fezolinetant and elinzanetant with placebo for vasomotor symptoms in menopausal women were included. TABULATION, INTEGRATION, AND RESULTS: We extracted the number of patients, mean age, body mass index (BMI), and number of patients who underwent oophorectomy. Data were examined with the Mantel-Haenszel method and 95% CIs. Heterogeneity was assessed with I2 statistics. R 4.3.2 was used for statistical analysis. Seven RCTs with 4,087 patients were included in the analysis. Fezolinetant and elinzanetant were associated with diminished vasomotor symptom frequency: fezolinetant 30 mg (mean difference 2.16, 95% CI, 1.54-2.79, I2 =0%), fezolinetant 45 mg (mean difference 2.54, 95% CI, 1.86-3.21, I2 =0%), and elinzanetant 120 mg (mean difference 2.99, 95% CI, 1.74-4.23, I2 =0%). Both drugs also showed a decrease in vasomotor symptom severity: fezolinetant 30 mg (mean difference 0.20, 95% CI, 0.09-0.33, I2 =0%), fezolinetant 45 mg (mean difference 0.24, 95% CI, 0.13-0.34, I2 =0%), and elinzanetant 120 mg (mean difference 0.36, 95% CI, 0.26-0.46, I2 =0%). Elinzanetant 120 mg showed a significant improvement in sleep quality (mean difference 4.65, 95% CI, 3.73-5.56, I2 =0%). Elinzanetant 120 mg was associated with the occurrence of drug-related adverse events (11.70% vs 20.75%, risk ratio [RR] 0.57, 95% CI, 0.39-0.82, I2 =19%) and headache (2.54% vs 8.0%, RR 0.32, 95% CI, 0.16-0.64, I2 =0%). CONCLUSION: In this meta-analysis, consistent results suggest that fezolinetant and elinzanetant are associated with beneficial outcomes in menopausal women with vasomotor symptoms. Elinzanetant provided a larger effect size in vasomotor symptom frequency and severity reduction and greatly improved sleep quality compared with fezolinetant. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023469952.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Menegaz de Almeida A, Oliveira P, Lopes L, et al. Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis. Obstet Gynecol. 2025. PMID: 39746208. doi:10.1097/AOG.0000000000005812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。